Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs

Arthritis Research and Therapy

Volumn 8, Issue 2, 2006, Pages

  López, Patricia ^a   Gómez, Jesús ^b   Mozo, Lourdes ^b   Gutiérrez, Carmen ^b   Suárez, Ana ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; DRUG COMBINATION; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METABOLISM; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; AGED; ANTIMALARIALS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; INTERLEUKIN-10; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34948862550     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1897     Document Type: Article

References (34)

1. Rynes RI: Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol 1997, 36:799-805.
2. MacIntyre AC, Cutler DJ: Role of lysosomes in hepatic accumulation of chloroquine. J Pharm Sci 1988, 77:196-199.
3. Macfarlane DE, Manzel L: Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol 1998, 160:1122-1131.
4. Karres I, Kremer JP, Dietl I, Steckholzer U, Jochum M, Ertel W: Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am J Physiol 1998, 274:R1058-R1064.
5. Seitz M, Valbracht J, Quach J, Lotz M: Gold sodium thiomalate and chloroquine inhibit cytokine production in monocytic THP-1 cells through distinct transcriptional and posttranslational mechanisms. J Clin Immunol 2003, 23:477-484.
6. Zhu X, Ertel W, Ayala A, Morrison MH, Perrin MM, Chaudry IH: Chloroquine inhibits macrophage tumour necrosis factoralpha mRNA transcription. Immunology 1993, 80:122-126.
7. Weber SM, Levitz SM: Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism. J Immunol 2000, 165 1534-1540.
8. Kroeger KM, Steer JH, Joyce DA, Abraham LJ: Effects of stimulus and cell type on the expression of the -308 tumour necrosis factor promoter polymorphism. Cytokine 2000, 12:110-119.
9. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997, 94 3195-3199.
10. Suarez A, Lopez P, Mozo L, Gutierrez C: Differential effect of IL10 and TNF{alpha} genotypes on determining susceptibility to discoid and systemic lupus erythematosus. Ann Rheum Dis 2005, 64 1605-1610.
11. Suarez A, Castro P, Alonso R, Mozo L, Gutierrez C: Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 2003, 75:711-717.
12. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997, 24:1-8.
13. Lopez P, Mozo L, Gutierrez C, Suarez A: Epidemiology of systemic lupus erythematosus in a northern Spanish population: Gender and age influence on immunological features. Lupus 2003, 12 860-865.
14. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
15. Salmeron G, Lipsky PE: Immunosuppressive potential of antimalarials Am J Med 1983, 75:19-24.
16. Hong Z, Jiang Z, Liangxi W, Guofu D, Ping L, Yongling L, Wendong P, Minghai W: Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Int Immunopharmacol 2004, 4:223-234.
17. Weber SM, Chen JM, Levitz SM: Inhibition of mitogen-activated protein kinase signaling by chloroquine. J Immunol 2002, 168 5303-5309.
18. Hugosson E, Montgomery SM, Premji Z, Troye-Blomberg M, Bjorkman A: Higher IL-10 levels are associated with less effective clearance of Plasmodium falciparum parasites. Parasite Immunol 2004, 26 111-117.
19. Aringer M, Feierl E, Steiner G, Stummvoll GH, Hofler E, Steiner CW, Radda I, Smole JS, Graninger WB: Increased bioactive TNF in human systemic lupus erythematosus: Associations with cell death. Lupus 2002, 11:102-108.
20. Atzeni F, Sarzi-Puttini P, Doria A, Iaccarino L, Capsoni F: Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: A review. Autoimmun Rev 2005, 4:144-152.
21. Rood MJ, van Krugten MV, Zanelli E, van der Linden MW, Keijsers V, Schreuder GM, Verduyn W, Westendorp RG, de Vries RR, Breedveld FC, Verweij CL, Huizinga TW: TNF-308A and HLADR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum 2000, 43:129-134.
22. Sullivan KE, Wooten C, Schmeckpeper BJ, Goldman D, Petri MA: A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus erythematosus in African-Americans. Arthritis Rheum 1997, 40:2207-2211.
23. Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, Inman RD, Kivitz A, Zhou L, Solinger A, Tsuji W: Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005, 64:1557-1562.
24. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
25. Reimold AM: New indications for treatment of chronic inflammation by TNF-alpha blockade. Am J Med Sci 2003, 325:75-92.
26. Suryaprasad AG, Prindiville T: The biology of TNF blockade. Autoimmun Rev 2003, 2:346-357.
27. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D: Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005, 52:2693-2696.
28. Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004, 50 2750-2756.
29. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR: ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001, 120:1347-1355.
30. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D: Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003, 48:1849-1852.
31. Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, Lundkvist I, Andersson P, Hermansson Y, Harju A, Klareskog L, Bratt J: Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003, 62:526-529.
32. Anolik JH, Aringer M:CNew treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 2005, 19:859-878.
33. Smolen JS, Steiner G, Aringer M: Anti-cytokine therapy in systemic lupus erythematosus. Lupus 2005, 14:189-191.
34. Aringer M, Graninger WB, Steiner G, Smolen JS: Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study. Arthritis Rheum 2004, 50:3161-3169.